Company intelligence / Profile preview

Napo Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Napo Therapeutics is investigating an innovative and first-in-class drug for short bowel syndrome and congenital diarrheal disorders, utilizing an active ingredient extracted from the Croton lechleri tree sap

Therapeutic areas: Gastroenterology
Modalities: Small molecules (derived from Croton lechleri tree sap)
Industry: Biotech

Drug pipeline

1 asset

crofelemer

Pre-clinical

Indications: Short bowel syndrome, Congenital diarrheal disorders

Beyond the preview

Go deeper on Napo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Napo Therapeutics.

Explore the full profile